This is the authors' abstract. We don't add key points for this paper.
Nivolumab plus chemotherapy did not significantly improve PFS versus chemotherapy in patients with EGFR-mutated metastatic NSCLC previously treated with EGFR TKIs. No new safety signals were identified.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mok et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: